ALNY — ALNYLAM PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1178670 ·
Last close
$147.82
Market Cap
$19.80B
52W High
$479.79
52W Low
$146.51
ADV30
2,711,120
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,458,086,000 | 1,096,336,000 | 345,798,000 | 2,167,335,000 | 7,994,672,000 | 1,754,340,000 | 4,390,820,000 |
| Jun 2026 | 1,290,948,000 | 992,497,000 | 231,441,000 | 164,494,000 | 5,558,769,000 | 1,708,318,000 | 4,204,651,000 |
| Mar 2026 | 1,167,175,000 | 956,053,000 | 268,636,000 | 205,991,000 | 5,129,547,000 | 1,710,779,000 | 4,054,167,000 |
| Dec 2025 | 1,097,033,000 | 829,310,000 | 131,718,000 | 186,419,000 | 4,966,331,000 | 1,657,250,000 | 4,177,155,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$901,768,000
Investing CF
$-737,903,000
Financing CF
$115,619,000
CapEx
$-149,637,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$19.26
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,164,704,000
Inventory
$105,907,000
Receivables
$1,084,905,000
ST Investments
$1,832,915,000
EBIT TTM
$1,221,452,000
Pretax Income TTM
$856,406,000
Interest Exp TTM
$365,046,000
Analysts
27
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,013,241,856
EBITDA
$1,033,027,008
Free Cash Flow
$327,232,512
Enterprise Value
$21,509,302,272
Total Cash
$3,587,255,040
Total Debt
$2,996,858,112
Shares Out
133,937,576
Trailing EPS
$19.80
Book Value
$26.92
ROE
138.1%
ROA
9.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,713,937,000 | 501,578,000 | 313,747,000 | 4,966,331,000 | 4,177,155,000 | 789,176,000 | 524,080,000 |
| Dec 2024 | 2,248,243,000 | -176,885,000 | -278,157,000 | 4,239,983,000 | 4,172,895,000 | 67,088,000 | -8,312,000 |
| Dec 2023 | 1,828,292,000 | -282,175,000 | -440,242,000 | 3,829,880,000 | 4,050,524,000 | -220,644,000 | 104,156,000 |
| Dec 2022 | 1,037,418,000 | -785,072,000 | -1,131,156,000 | 3,546,359,000 | 3,704,582,000 | -158,223,000 | -541,274,000 |
TTM Snapshot
Revenues TTM
$4,804,182,000
NetIncome TTM
$807,988,000
OpCashFlow TTM
—
Assets (Latest)
$5,558,769,000
Forward EPS
$11.41
Max Pain — expiry 2026-12-18
max pain strike: $185.00 · spot: $150.15 · call oi: 4,919 · put oi: 5,166
Expected Move to 2026-12-18:
±$16.45
(10.96%) —
implied range
$133.70 –
$166.60
· ATM straddle on $150.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VTRS | Viatris Inc | $22.79B | $19.88 | — |
| ASND | Ascendis Pharma A/S | $16.84B | $255.96 | — |
| UTHR | UNITED THERAPEUTICS Corp | $23.81B | $559.10 | — |
| BBIO | BridgeBio Pharma, Inc. | $15.23B | $78.18 | — |
| JAZZ | Jazz Pharmaceuticals plc | $15.18B | $236.45 | — |
News headlines (Yahoo Finance, 1h cache)
Alnylam to Webcast Presentations at Upcoming December Investor Conferences
2026-11-20 13:00 · Yahoo
Alnylam (ALNY) Stock Looks Undervalued As Shares Fell 68%
2026-11-19 18:17 · Yahoo
Alnylam Pharmaceuticals (ALNY) Stock Dropped, So What Is Driving Attention Now?
2026-11-19 16:08 · Yahoo
Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years
2026-11-19 12:00 · Yahoo
Alnylam Stock Trades Below Its Pre-$1 Billion Buyback Price
2026-11-17 19:45 · Yahoo
What Is Driving Alnylam Stock?
2026-11-16 21:03 · Yahoo
What Moved Alnylam Stock?
2026-11-12 15:13 · Yahoo
RNA Interference (RNAi) - Global Strategic Business Report: Capture the US$8 Billion 2032 Market as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Qiagen, Benitec BioPharma, and Silence Therapeutics
2026-11-12 14:06 · Yahoo
Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD
2026-11-10 15:00 · Yahoo
Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
2026-11-09 15:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.